Back to Multiple Sclerosis
NCT02907177
NCT02907177
Who may be able to join
Who might be able to join this trial:
- You must be willing to sign a consent form before any study procedures begin.
- Women who could become pregnant must have a negative pregnancy test and use reliable birth control during the study.
- You must have been diagnosed with a relapsing form of multiple sclerosis (MS) — either relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) that still has relapses — based on specific diagnostic guidelines from 2010.
- You must have been taking a medication called DMF (dimethyl fumarate) for at least 6 months before the screening appointment.
- Your MS must still be showing signs of activity after at least 3 months of taking DMF.
- You must be able to walk (with or without aid) and score between 0 and 6.0 on a standard MS disability scale called the EDSS.
Who may not be able to join:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
- People whose MS has been progressive from the very beginning (called primary progressive MS or progressive relapsing MS).
- People who have had an MS relapse that started within the 30 days before their initial disability assessment.
- Anyone whose personal circumstances or health conditions might prevent them from fully participating in the study, as judged by the study doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Terminated
Phase
Phase 3
Sponsor
Actelion
Registry
clinicaltrials_gov
Start date
30 March 2017
Est. completion
26 March 2020
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇹 Italy
🇲🇽 Mexico
🇵🇱 Poland
🇵🇹 Portugal
🇷🇺 Russia
🇪🇸 Spain
🇨🇭 Switzerland
🇬🇧 United Kingdom
🇺🇸 United States
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualized Confirmed Relapse Rate (ARR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.